Vaccination against tuberculosis is a practice recommended by the World Health Organization at birth in areas where tuberculosis is endemic (www.who.int). This procedure requires the intramuscular inoculation of the Bacillus Calmette-Guèrin (BCG), which is a live, attenuated strain of Mycobacterium bovis. A possible consequence of this inoculation is the development of infection that ranges from localized lesions, as subcutaneous abscesses in the site of inoculation, to disseminated disease. 1, 2 The majority of patients who develop disseminated disease after BCG vaccination are those affected with genetic disorders with reduced T-cell number and function, and in some cases also B cells or NK cells (SCID), which is undiagnosed before vaccination. 3, 4 Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment for SCID, but a high transplant-related mortality rate is reported in the case of disseminated BCG infection. 5 We report a case of successful management of a disseminated BCG infection in a child with a diagnosis of X-linked SCID undergoing allo-HSCT.
A 2.5-year-old male child, born in a North-African country to nonconsanguineous parents, was admitted to our hospital to receive allo-HSCT for X-linked SCID (CD3 − , CD16/56 − , CD19+, with IL-2RG gene mutation). He received the Moreau BCG vaccine at 3 days of age in the left deltoid muscle and, in the following weeks, developed a subcutaneous nodule at the site of injection with mild inflammatory signs that remained stable over time with a slow chronic course.
On admission, he was seen to be in poor general condition, with severe psychomotor and growth delay, chronic rotavirus diarrhea and oral-esophageal candidiasis with hyporexia. He presented a subcutaneous nodule on the left arm at the site of the previous BGC inoculation and an axillary satellite lymph node. A biopsy of both lesions showed a histiocytic granulomatous infiltrate with multinucleated giant cells and caseation necrosis, and the Ziehl-Nielsen staining revealed numerous acid-fast bacilli (AFB), but the culture was negative. No other skin lesions were present. A chest CT-scan revealed the presence of some calcified pulmonary nodules. A diagnosis of regional BCG infection was made and therapy with isoniazid, rifampin and ethambutol was started.
After antimycobacterial therapy for a period of 4 months, an allogeneic HSCT was performed at the age of 33 months with an HLA-9/10-matched unrelated donor as no related donor was available, using a treosulfan-based myeloablative conditioning regimen. GvHD prophylaxis included antilymphocyte serum, cyclosporine and mycophenolate mofetil.
During the conditioning regimen the patient developed a fluctuant nodule on the right thigh (size 23 × 12 × 12.5 mm neutropenia, the patient received empirical therapy with amikacin, levofloxacin and meropenem, added to previous anti-BCG therapy, to treat a possible infection due to neutropenia and a possible further dissemination of BGC infection. On day +9 his clinical condition worsened and the chest CT scan showed a lesion on the left lung; moreover, ultrasound of a subcutaneous nodule on the right thigh showed signs of colliquation. Bronchoalveolar lavage microscopic examination showed the presence of numerous AFB, but the culture was again negative.
Three gastric aspirates and abdominal ultrasound were also performed, and all were negative. No other clinical signs of possible infectious localization were observed and all blood cultures (included those for Mycobacteria) were negative. Neutrophil and platelet engraftments were achieved on day 14 after HSCT with complete donor chimerism (short tandem repeat), and meropenem was withdrawn. On day +30 subcutaneous nodules were reduced both in number and size, and no new skin lesion appeared. Thirty-seven days after transplant, the child developed acute-GvHD grade 3 of the liver, with less and rapidly resolving involvement of the skin and gut, with complete response obtained with steroids at 2 mg/kg plus ursodeoxycholic acid and consolidated with extracorporeal lympho-photopheresis. On day +90, considering the good clinical status of the patient, amikacin was withdrawn, but on day +110, during steroid tapering and in the presence of full immune reconstitution, the right leg nodule appeared purulent (Figure 1c) . Ziehl-Nielsen staining of biopsy tissues revealed numerous AFB, subsequently identified as M. Bovis/BCG by PCR. Antimycobacterial therapy (isoniazid, rifampin, ethambutol and levofloxacin) was continued and steroid treatment was increased again. Levofloxacin was stopped after a total of 6 months. After a total of 21 months of treatment (from March 2013 to December 2014), 18 months after allo-HSCT, skin lesions had completely disappeared and therefore antimycobacterial therapy was stopped. Four months after discontinuation of antimycobacterial treatment, still receiving immunoduppression with cyclosporin and imatinib, the patient is thriving normally and still in clinical and radiological remission of BCG infection, with complete HSCT engraftment.
BCG vaccination is currently administered in newborns in most developing countries to prevent severe infection with Mycobacterium tuberculosis. In normal subjects BCG vaccination is followed by infiltration measuring 10 mm or less at least 14 days after inoculum, with well-healed scar formation no later than 4 months thereafter. 6 Any course deviating from this sequence should be considered a complication. In patients with T-cell defects systemic dissemination of the organism can occur, but true infection with signs and symptoms of mycobacterial disease is very rare, with an incidence rate ranging from 1 to 4.3 cases per 1 million infants vaccinated; in these cases the mortality rate is very high (60%). [4] [5] [6] [7] [8] Our patient affected with T-B+ SCID presented a localized infection at the site of inoculum and satellite lymph node, a consequence of BCG infection that became disseminated during pre-engraftment bone marrow aplasia induced by allo-HSCT conditioning regimen, despite 4 months of previous, presumptively effective anti-BCG therapy with isoniazid, rifampin and ethambutol. [9] [10] [11] This dissemination was finally controlled by this combination of antibiotics, with temporary addition of amikacin (3 months) and levofloxacin (6 months) 11, 12 in the early postengraftment period, and immune reconstitution (despite immunosuppression for management of GvHD). A comprehensive Medline search using the keywords 'cutaneous complication' and 'BCG vaccination', without any other filter, showed that skin manifestations like subcutaneous nodules, rash, ulcers and erythema in SCID patients with disseminated BCG have been described. 3, 9, 10, 12 The largest series was reported by Talbot et al.
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with 37 patients vaccinated with BCG of whom 28 (75%) have been defined as definite disseminated BCG disease and 9 as probable disseminated BCG disease. Only seven of them (21% of definite disseminated infections, 11% of probable disseminated infections and 19% of all cases) showed cutaneous dissemination. Interestingly, our patient presented a worsening of skin lesions at day +110 after HSCT in the presence of full immune reconstitution and steroid tapering, which could have been due to immunosuppression related to recurrent acute GvHD, 13 or due to immune reconstitution inflammatory syndrome (IRIS), as described by Searle et al.
14 in 2010, who reported inflammatory BCG adenitis associated with IRIS occurring 83-164 days after allo-HSCT in four children previously vaccinated with BCG. IRIS-associated skin spreading of BCG vaccine has also been described in HIV-positive children after immune reconstitution following antiretroviral therapy. 12 At present the better management strategy for prevention and treatment of BCG dissemination in children vaccinated against tuberculosis and requiring allo-HSCT is unknown. We hypothesize that the 4 months of (presumptively) effective anti-BCG therapy 11 prevented deep organ but not skin dissemination of BCG during the pre-engraftment bone marrow aplasia. Even so a complete resolution was achieved only with prolonged anti-BCG therapy associated with complete immune reconstitution. It is possible that a longer (at least 6 months) anti-BCG therapy before allo-HSCT could be more effective, even in the presence of local (site of inoculum and regional lymph node) infection by BCG, and that this regimen can be reinforced with two or three other drugs in case of dissemination of BCG before immune reconstitution. We suggest the continuation of anti-BCG therapy for at least another 12 months' post engraftment, in the presence of complete bone marrow recovery and a correct (and a little bit lucky) management of post-transplant complications like GvHD. Figure 1. (a, b) Subcutaneous nodules on right leg and both elbows appeared on day 0; (c) a worsening of subcutaneous right leg nodule appeared on day +110 after HSCT. A full color version of this figure is available at the Bone Marrow Transplantation journal online.
